NASDAQ:MNOV - MediciNova Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$8.93 -0.04 (-0.45 %)
(As of 07/20/2018 01:03 AM ET)
Previous Close$8.97
Today's Range$8.84 - $9.00
52-Week Range$4.40 - $14.50
Volume86,400 shs
Average Volume223,041 shs
Market Capitalization$369.34 million
P/E RatioN/A
Dividend YieldN/A
Beta0.21
MediciNova logoMediciNova, Inc., a biopharmaceutical company, focuses on acquiring and developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company's product candidate includes MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for the treatment of neurological disorders consisting of primary and secondary progressive multiple sclerosis; amyotrophic lateral sclerosis; and substance dependence and addiction. Its product pipeline also comprises MN-221 (bedoradrine), a selective -adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis, idiopathic pulmonary fibrosis, and other fibrotic diseases; and MN-029 (denibulin), a tubulin binding agent to treat solid tumor cancers. The company was founded in 2000 and is headquartered in La Jolla, California.

Receive MNOV News and Ratings via Email

Sign-up to receive the latest news and ratings for MNOV and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:MNOV
CUSIPN/A
Phone858-373-1500

Debt

Debt-to-Equity RatioN/A
Current Ratio53.42
Quick Ratio53.42

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$1.07 per share
Price / Book8.35

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-11,160,000.00
Net MarginsN/A
Return on Equity-27.91%
Return on Assets-25.35%

Miscellaneous

Employees9
Outstanding Shares41,130,000
Market Cap$369.34

MediciNova (NASDAQ:MNOV) Frequently Asked Questions

What is MediciNova's stock symbol?

MediciNova trades on the NASDAQ under the ticker symbol "MNOV."

How were MediciNova's earnings last quarter?

MediciNova, Inc. (NASDAQ:MNOV) issued its quarterly earnings data on Wednesday, April, 25th. The biopharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter. View MediciNova's Earnings History.

What price target have analysts set for MNOV?

1 brokers have issued 12-month target prices for MediciNova's stock. Their predictions range from $22.00 to $22.00. On average, they anticipate MediciNova's share price to reach $22.00 in the next twelve months. This suggests a possible upside of 146.4% from the stock's current price. View Analyst Ratings for MediciNova.

What is the consensus analysts' recommendation for MediciNova?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MediciNova in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."

Who are some of MediciNova's key competitors?

Who are MediciNova's key executives?

MediciNova's management team includes the folowing people:
  • Dr. Yuichi Iwaki, Co-Founder, Pres, CEO & Exec. Director (Age 68)
  • Mr. Ryan J. Selhorn, CFO & Principal Accounting Officer (Age 36)
  • Mr. Masatsune Okajima, Head of Japanese Office and VP (Age 50)
  • Dr. Kazuko Matsuda M.D., Ph.D., MPH, Chief Medical Officer (Age 52)
  • Mr. Geoffrey G. O'Brien J.D., M.B.A., VP (Age 49)

Has MediciNova been receiving favorable news coverage?

Headlines about MNOV stock have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies negative and positive news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. MediciNova earned a media sentiment score of 0.08 on Accern's scale. They also assigned media stories about the biopharmaceutical company an impact score of 45.48 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

Who are MediciNova's major shareholders?

MediciNova's stock is owned by a number of of institutional and retail investors. Top institutional investors include SATOMI HAJIME (5.30%). Company insiders that own MediciNova stock include Yoshio Ishizaka and Yutaka Kobayashi. View Institutional Ownership Trends for MediciNova.

How do I buy shares of MediciNova?

Shares of MNOV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is MediciNova's stock price today?

One share of MNOV stock can currently be purchased for approximately $8.93.

How big of a company is MediciNova?

MediciNova has a market capitalization of $369.34 million. MediciNova employs 9 workers across the globe.

How can I contact MediciNova?

MediciNova's mailing address is 4275 EXECUTIVE SQUARE SUITE 300, LA JOLLA CA, 92037. The biopharmaceutical company can be reached via phone at 858-373-1500 or via email at [email protected]


MarketBeat Community Rating for MediciNova (NASDAQ MNOV)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  119 (Vote Outperform)
Underperform Votes:  63 (Vote Underperform)
Total Votes:  182
MarketBeat's community ratings are surveys of what our community members think about MediciNova and other stocks. Vote "Outperform" if you believe MNOV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MNOV will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.